The CHANCE study: Persistent hair disorder-related quality of life in women with nonmetastatic breast cancer

Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research

Related Links:

British Journal of Cancer, Published online: 17 September 2019; doi:10.1038/s41416-019-0576-5Comment on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines”
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
British Journal of Cancer, Published online: 17 September 2019; doi:10.1038/s41416-019-0577-4Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Introduction: Endocrine therapies (ETs) are associated with alopecia (EIA) in 15-25% of patients. There are no approved therapies for EIA. The purpose of this review is to provide dermatologists and oncologists with a foundation for the practical understanding of 5 α-reductase inhibitors and spironolactone for breast cancer patients and survivors with alopecia attributed to ETs, including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Dignitana, a company out of Lund, Sweden, won FDA clearance and is now distributing its DigniCap Delta scalp cooling system in the U.S. The University of California, San Francisco (UCSF) will be the first recipient in America of the fourth generation...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Oncology Source Type: blogs
Conclusions: The scalp cooling demonstrated the prevention of alopecia and safety for Japanese patient. In addition, compared to the control group, scalp cooling resulted in faster recovery in hair volume even in the patient who failed scalp cooling during the chemotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 15 July 2019; doi:10.1038/s41416-019-0520-8Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractPatients with breast cancer desire to avoid chemotherapy-induced alopecia because it induces mental stress during treatment. Scalp cooling can suppress chemotherapy-induced alopecia without increasing the risk of scalp metastasis; however, in certain cases, alopecia cannot be prevented. The use of properly fitted scalp cooling caps has not yet been explored in Asian patients. Here, we report a case of hair regrowth using a properly fitted scalp cooling cap during adjuvant chemotherapy for breast cancer. A 51-year-old Japanese woman who was recalled by screening mammography for grouped amorphous calcifications and a...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
This study was to investigate the role and mechanism of YH0618 in ameliorating DOX-induced toxicity by in vitro and in vivo experiments. YH0618 selectively attenuated DOX-induced growth inhibition and apoptosis in human normal liver L02 cells and kidney HEK-293 cells, and simultaneously potentiated the anti-cancer effect of DOX in breast cancer MCF-7 and MDA-MB-231 cells by apoptosis pathways. Western blotting results revealed that YH0618 attenuated DOX-induced apoptosis in normal liver and kidney cells through FOXO4-mediated mitochondria-dependent mechanism. Animal experiments demonstrated that, YH0618 did not interfere i...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion: Coincidence of two monogenic autosomal dominant tumor syndromes is extremely rare, representing significant therapeutic and cancer surveillance challenges. Due to the wider use of next generation sequencing in clinical practice similar situations may occur more frequently.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we reviewed major human studies on the health risks of radiation exposure and showed that sex-related factors may potentially influence the long-term response to radiation exposure. Available data suggest that long-term radiosensitivity in women is higher than that in men who receive a comparable dose of radiation. The report on the biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences, United States emphasized that women may be at significantly greater risk of suffering and dying from radiation-induced cancer than men exposed to the same dose of radiation....
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Academies | Alopecia | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Dermatology | Endocrine Therapy | Skin | Study | Women